Comments
Cadila Healthcare on Friday said Zydus’ Nesher Pharmaceuticals has received final nod from the US health regulator to market generic version of Adderall XR capsules in the US.
The final approval from the USFDA is to market Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate extended-release capsules in the strengths of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg, Cadila Healthcare said in a filing to BSE.
The product is a generic version of Adderall XR capsules and will be manufactured at Nesher Pharmaceuticals’ manufacturing facility at St Louis in the US, it added.
The drug is indicated for the treatment of attention-deficit hyperactivity disorder (ADHD), it said.
The group now has 269 approvals and has so far filed over 360 abbreviated new drug applications (ANDAs) since the commencement of its filing process, it added.
Shares of Cadila Healthcare closed at Rs 228.45 per scrip on BSE, down 1.10 per cent from the previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.